Frost & Sullivan

MARCH 22, 2024

However, the pharma/biopharma industry shows overall stagnant R&D activity. growth from 2023 to 2024. What is driving transformation in the pharma industry? Small-to-mid and emerging biopharma players contribute over 16%. Are you considering drug discovery ecosystem partnerships to survive and thrive?

Biopharma 52

Biopharma Ecosystems Biotech Contract research organization 52

Frost & Sullivan

JUNE 24, 2024

The sessions of the American Society of Clinical Oncology ( ASCO ) 2024 conference focused on this year’s theme – The Art and Science of Cancer Care: From comfort to cure. During ASCO 2024, AbbVie unveiled new data from its ADC platform, which is now being used for the development of therapies that specifically target solid tumors.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Collaboration Ecosystems 52

Frost & Sullivan

MARCH 16, 2025

The global proteomics industry is poised for significant expansion between 2024 and 2030, driven by advances in research and pharmaceutical applications. The Proteomics Ecosystem: Whos Driving Innovation? This blog explores the key factors influencing the industry, the competitive landscape, and emerging growth opportunities.

Biopharma 52

Biopharma Strategic alliances Strategic partnership Ecosystems 52

Frost & Sullivan

JANUARY 23, 2025

The 43rd JP Morgan Healthcare Conference , held from January 1316, 2025, in San Francisco, brought together a vibrant ecosystem of global pharma stakeholders, innovative startups, emerging biotech companies, and investors. South Koreas Investments : Lotte Biologics invested $3.3

Biotechnology 52

Biotechnology Mergers and acquisition activities Biotech Biopharma 52